actinium has been researched along with Leukemia, Myeloid, Acute in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrasquillo, JA; Cicic, D; Douer, D; Frattini, MG; Jurcic, JG; Larson, SM; Maslak, PG; McDevitt, MR; Pandit-Taskar, N; Park, JH; Rosenblat, TL; Scheinberg, DA | 1 |
| Allen, KJH; Dadachova, E; Dawicki, W; Garg, R; Geoghegan, EM; Ludwig, DL | 1 |
| Jurcic, JG | 1 |
| Featherstone, C | 1 |
1 review(s) available for actinium and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bismuth; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Radiochemistry; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals | 2018 |
1 trial(s) available for actinium and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal, Humanized; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
2 other study(ies) available for actinium and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Topics: Actinium; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Alpha-particle-emitting radioisotopes coupled to antibody for acute myeloid leukaemia treatment.
Topics: Actinium; Alpha Particles; Bismuth; Humans; Leukemia, Myeloid, Acute; Radioimmunotherapy; Radioisotopes | 1997 |